Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoadsorption + rituximab + IVIG for anti-HLA antibody reduction before allo-HSCT
ChiCTR2300076065Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and immune globulin in Antibody-mediated allograft rejection (AMR) and hematopoietic malignancies, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Incidence of reduction of anti-HLA antibody MFI values to within 5000 at end of treatment. Started Oct 2023; status: recruiting.
02
Drugs
rituximabimmune globulin
03
Conditions
Antibody-mediated allograft rejection (AMR)hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2300076065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076065.